Imcyse is a clinical-stage biopharmaceutical company pioneering the development of a new class of active, specific immunotherapies for the treatment of severe, chronic autoimmune diseases.
The Imcyse technology platform has the potential to address a wide range of indications in the vast field of immunology. It is based on the discovery of modified synthetic peptides - ImotopesTM, which specifically block improper immune resp...
Imcyse is a clinical-stage biopharmaceutical company pioneering the development of a new class of active, specific immunotherapies for the treatment of severe, chronic autoimmune diseases.
The Imcyse technology platform has the potential to address a wide range of indications in the vast field of immunology. It is based on the discovery of modified synthetic peptides - ImotopesTM, which specifically block improper immune responses. Thus representing a next generation, potentially curative approach to severe chronic autoimmune diseases for which there is no satisfactory therapeutic alternative.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.